

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Marc G. Jacquemin &
Jean-Marie R. Saint-Remy

Serial No.: 10/044,569

Filed: January 11, 2002

Patent: Method and Pharmaceutical
Composition for Preventing
and/or Treating Systemic
Inflammatory Response
Syndrome

Honorable Director of Patents
and Trademarks
Washington, DC 20231


INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In connection with the subject application, and in accordance with the provisions of 37 CFR § 1.97-1.99, submitted herewith is a copy of form PTO-1449 and copies of the references cited therein.

Respectfully submitted,

April 10, 2002
Date


Mark A. Hagedorn
Reg. No. 44,731
Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, Illinois 60690-2786
312-368-5945 Direct Line
312-368-0034 Facsimile

One of the Attorneys for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

APR 16 2002

Complete if Known

| | |
|------------------------|---|
| Application Number | 10/044,569 |
| Filing Date | 01/11/2002 |
| First Named Inventor | Marc G. Jacquemin & Jean-Marie Saint-Remy |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 0522-1769.1 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|-----------------|--------------------------------------|--------------------------------|--|--|
| | | Number | Kind Code ² (if known) | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|-------------------------|---------------------|---------------------------------|--------------------------------|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind ⁵ (if known) | | | | |
| | | | W0 97 26010 | | 07/24/1997 | SMITHKLINE BEECHAM | Pg6, Ln 13- Pg8, Ln2 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known

| | |
|------------------------|---|
| Application Number | 10/044,569 |
| Filing Date | 01/11/2002 |
| First Named Inventor | Marc G. Jacquemin & Jean Marie Saint-Remy |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 0522-1769.1 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|---|----------------|
| | | J. BATLLE ET AL.: "Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction." ANNALS OF HEMATOLOGY, vol. 75, no. 3, September 1997 (1997-09), pages 111-115, XP 000906715. | |
| | | J. INGERSLEV ET AL.: "Applications of immunoperoxidase techniques in specificity testing of monoclonal antibodies (Mabs) against von Willebrand factor (vWF)." CLINICA CHIMICA ACTA, vol. 174, no. 1, 1988, pages 65-82, XP000906709. | |
| | | M. GAWRYL ET AL.: "Inactivation of factor VIII coagulant activity by two different types of human antibodies." BLOOD, vol. 60, no. 5, November 1982 (1982-11), pages 1103-1109, XP000892192. | |
| | | B. LY ET AL.: "Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes." SCANDINAVIAN JOURNAL OF HAEMATOLOGY, vol. 28, no. 2, February 1982 (1982-02), pages 132-140, XP000892196. | |
| | | M. JACQUEMIN ET AL.: "Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor." BLOOD, vol. 92, no. 2, 15 July 1998 (1998-07-15), pages 496-506, XP000906844. | |
| | | M JACQUEMIN ET AL.: "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor." BLOOD, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 156-163, XP002150704. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.